ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0174

Imaging Neoangiogenesis in Rheumatoid Arthritis II (INIRA II): Whole-body Synovial Uptake of 99mTc-Maraciclatide Correlates with Power Doppler Ultrasound and Serum Neoangiogenic Biomarkers

Laura Attipoe1, Sujith Subesinghe2, Cristina Blanco Gil2, Maria Opena2, Kathryn Steel3, Sarah Ryan3, Sam Norton3, Mark Rosser4, Gary Cook3, Andrew P Cope3 and Toby Garrood2, 1Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, London, 3King's College London, London, United Kingdom, 4Serac Healthcare, London, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Biomarkers, Imaging, Nuclear Medicine, rheumatoid arthritis, tracer

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Imaging of Rheumatic Diseases Poster (0149–0182)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: 99mTc-maraciclatide (99mTc-M) (Serac Healthcare) is a radio-labelled tracer which binds with high affinity to integrin αvβ3, a cell-adhesion molecule up-regulated on neoangiogenic blood vessels. It therefore has the potential to image synovial inflammation at the whole-body level.

Our group has previously published interim results showing that 99mTc-M uptake correlated with power Doppler ultrasound (PDUS) in 25 patients with rheumatoid arthritis (RA)1. This study now explores correlation with PDUS and serum biomarkers in a larger group of patients.

Methods: 50 patients with RA (mean disease duration 12.8 (SD 8.2, 1-35 range) years, mean DAS28-CRP 4.8 (1.2, 1.9-7.1)) fulfilling ACR 2010 classification criteria were recruited. Patients had an ultrasound scan of 40 joints. Each joint was scored on a scale of 0-3 for greyscale and PD with a total score calculated per patient.

Within 3 hours patients were injected with 740 MBq of 99mTc-M. Whole body planar views, and static hand and foot views were taken 2 hours after injection. Acquisition time was 20 minutes for whole body and 20 minutes for hand and foot views. 99mTc-M images were scored as positive or negative uptake for each joint (binary score). A quantitative (geometric mean, GM) score was calculated for each joint where there was uptake with this corrected for background uptake. Total binary and GM scores per patient were calculated.

Sera was taken from each patient on the day of imaging with analysis of 24 biomarkers via multiplex bead assay.

Total PDUS and 99mTc-M scores were tested for correlation using Pearson’s coefficient of determination (r2). Spearman’s rank correlation (rs) was used to evaluate correlation between serum biomarkers and imaging modalities. Significance was set at p< 0.05.

Results: 99mTc-M uptake was clear on visual assessment of small and large joints (Figure 1). Strong correlation was observed when total PDUS was compared to total binary (r2 = 0.82, Figure 2) as compared to total GM 99mTc-M scores (r2 = 0.72). Total GSUS scores also correlated with total binary (r2 = 0.74) and total GM 99mTc-M scores (r2 = 0.60). p was < 0.001 for all values.

There was substantial inter-assessor agreement with a kappa of 0.79 for PDUS, and 0.82 for 99mTc-M scan binary scoring respectively. Concordance correlation coefficient was strong at 0.82 for GM scoring.

99mTc-M uptake at a single joint level had a sensitivity of 78% (95% CI 73-83), specificity of 91% (89-92), positive predictive value (PPV) of 57% (53-61), and negative predictive value (NPV) of 96% (95-97). When assessing small joints alone, sensitivity was 78% (95% CI 72-83), specificity was 94% (93-96), PPV was 72% (67-77), and NPV was 96% (95-97).

There was moderate correlation between MMP3 and total binary (rs = 0.44, p = 0.002), and GM (rs = 0.52, p = 0.001) scores. There was statistically significant weak correlation between VEGF, IL6, YKL40, IL8 and both imaging modalities (Table 1).

Conclusion: 99mTc-M uptake is highly correlated with PDUS, and weakly to moderately correlated with serum biomarkers highlighting its potential as an alternative imaging modality that captures total synovial inflammatory load. Recruitment is underway to expand the data to a larger group of patients.

Reference
1. Attipoe L, Garrood T, Subesinghe S, et al. Imaging Neoangiogenesis in Rheumatoid Arthritis (INIRA): Whole-Body Synovial Uptake of a 99mTc-Labelled RGD Peptide Is Highly Correlated with Power Doppler Ultrasound – ACR Meeting Abstracts. Arthritis Rheumatol. 2019;71 (suppl. https://acrabstracts.org/abstract/imaging-neoangiogenesis-in-rheumatoid-arthritis-inira-whole-body-synovial-uptake-of-a-99mtc-labelled-rgd-peptide-is-highly-correlated-with-power-doppler-ultrasound/


Disclosures: L. Attipoe, None; S. Subesinghe, None; C. Blanco Gil, None; M. Opena, None; K. Steel, None; S. Ryan, None; S. Norton, None; M. Rosser, Serac Healthcare, 3; G. Cook, None; A. Cope, None; T. Garrood, None.

To cite this abstract in AMA style:

Attipoe L, Subesinghe S, Blanco Gil C, Opena M, Steel K, Ryan S, Norton S, Rosser M, Cook G, Cope A, Garrood T. Imaging Neoangiogenesis in Rheumatoid Arthritis II (INIRA II): Whole-body Synovial Uptake of 99mTc-Maraciclatide Correlates with Power Doppler Ultrasound and Serum Neoangiogenic Biomarkers [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/imaging-neoangiogenesis-in-rheumatoid-arthritis-ii-inira-ii-whole-body-synovial-uptake-of-99mtc-maraciclatide-correlates-with-power-doppler-ultrasound-and-serum-neoangiogenic-biomarkers/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/imaging-neoangiogenesis-in-rheumatoid-arthritis-ii-inira-ii-whole-body-synovial-uptake-of-99mtc-maraciclatide-correlates-with-power-doppler-ultrasound-and-serum-neoangiogenic-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology